Efficacy of delafloxacin against the biothreat pathogen Bacillus anthracis
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Sandra McCurdy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Melinta Therapeutics, 44 Whippany Rd, Morristown, NJ, USA. Hauptthemen laut MEDLINE: Bacillus anthracis, Anthrax. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Joint Science and Technology Office for Chemical and Biological Defense, Joint Program Manager for Chemical, Biological, Radiological, and Nuclear Medical.
Abstract (Originalsprache)
Objectives
To evaluate the in vitro activity and in vivo efficacy of delafloxacin against Bacillus anthracis, the causative agent of anthrax.
Methods
MICs were obtained according to CLSI guidelines for 30 virulent isolates and 14 attenuated antibiotic-resistant strains. For the in vivo efficacy study, mice were administered delafloxacin (30–62.5 mg/kg) subcutaneously, or ciprofloxacin (30 mg/kg) intraperitoneally beginning at either 24 or 48 ± 1 h post-challenge (post-exposure prophylaxis) and continued every 12 h for 14 days with study termination on day 30. The mean inhaled dose in the study was approximately 103 × LD50 equivalents, and the range was 87–120 × LD50.
Results
Delafloxacin (MIC90 = 0.004 mg/L) was 16-fold more potent than ciprofloxacin (MIC90 = 0.06 mg/L) against a 30-strain set of virulent B. anthracis. Against a panel of attenuated antibiotic-resistant strains, delafloxacin demonstrated potency ≥128-fold over that observed with ciprofloxacin. When evaluated in vivo, mice treated with all delafloxacin doses tested at 24 h post-challenge demonstrated equivalent survival compared with mice treated with the positive control ciprofloxacin. Because of the high challenge dose of spores, mice treated at 48 h showed rapid and high mortality in all groups including the positive control. Surviving animals in all delafloxacin- and ciprofloxacin-treated groups (24 and 48 h) showed complete splenic clearance of infection and <2.2 × 103 cfu/g lung tissue.
Conclusions
Given the high bar set by the 100 × LD50 challenge dose in this study, the results from delafloxacin treatment are promising for the treatment of inhaled anthrax.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Melinta Therapeutics, 44 Whippany Rd, Morristown, NJ, USA.
- Bacteriology Division, US Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter St., Fort Detrick, MD, USA.
- Pharmacology Consultant for Melinta Therapeutics, 15 Plane Tree Ln, Dix Hills, NY 11746, USA.
- Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), CBRN Medical, 110 Thomas Johnson Dr., Suite 300, Frederick, MD, USA.
ORCID-Profile: J Matthew Meinig
Förderung
- Joint Science and Technology Office for Chemical and Biological Defense
- Joint Program Manager for Chemical, Biological, Radiological, and Nuclear Medical
Zitieren
APA
McCurdy, S., Halasohoris, S. A., Babyak, A. L., Lembirik, S., Hoover, R., Hickman, M., Scarff, J., Klimko, C. P., Cote, C. K., & Meinig, J. M. (2023). Efficacy of delafloxacin against the biothreat pathogen Bacillus anthracis. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad015
Vancouver
McCurdy S, Halasohoris SA, Babyak AL, Lembirik S, Hoover R, Hickman M, et al. Efficacy of delafloxacin against the biothreat pathogen Bacillus anthracis. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad015
BibTeX
@article{McCurdy2023,
author = {McCurdy, Sandra and Halasohoris, Stephanie A and Babyak, Ashley L and Lembirik, Sanae and Hoover, Randall and Hickman, Mark and Scarff, Jennifer and Klimko, Christopher P and Cote, Christopher K and Meinig, J Matthew},
title = {Efficacy of delafloxacin against the biothreat pathogen Bacillus anthracis},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad015}
}
EUVIMED